Pfizer: Low Expectations Make Great Investments 10 comments
-
Font Size:
-
Print
- TweetThis
There is a difference between a great company and a great investment. Though they are many times one and the same, a great investment comes from paying the right price for a business that you understand. More often than not, the right price presents itself when short-term business issues distract the market from the true value of the business.
Pfizer (PFE) is a longtime industry leader, though not exactly “great” today. Its number one issue is the impending loss of Lipitor and the lack of meaningful late stage pipeline candidates to replace that significant loss.
One of the few bright spots today at Pfizer is the price at which today’s investors can buy the stock. At an $18 stock price, Pfizer shares are selling at a 32% discount to their estimated current value of $26 (using discounted cash flow analysis).
In addition, the stock has a dividend yield over 7%. In contrast to other high yielding companies with shaky balance sheets, Pfizer has $29 billion in cash and short term investments as of the most recent quarter. The dividend is secure.
Assuming that an investor buys shares today at $18 and holds them for three years, the compound annual growth rate of the total return (stock price appreciation plus dividends) is 20%. It’s worth noting that this analysis does not imply improved business conditions at Pfizer. It highlights that the stock is now being hated to the point where it has become irrationally priced and a worthwhile investment for those with a long-term focus.
Disclosure: Author holds a long position in PFE
Related Articles
|

























This article has 10 comments:
You probably got in around $26 and need the stock to get back to that point to break even.
The stock is absolute garbage, however the thing has been beaten down so much it is due for a run. So I guess now is as good a time as any for some asset gatherer to show up and do a pump and dump article on PFE. I guess after the beating this stock has taken the chances of you being wrong are pretty slim (though you never know)
Do yourself a favor, when it gets back to your break even point, sell it.
That way we do not have to endure these self serving, pump and dump articles
But with $11 billion net cash ($28 billion cash—$17 billion debt), why can't Pfizer just buy several companies that have new blockbuster drugs in the pipeline? They have a couple years to do this before their own drugs go off-patent. I think they are waiting and watching right now.
What's wrong with my thinking?
There is nothing wrong with your thinking. But the "stock" of PFE is crap VS the company. Until the stock starts acting better, what the company does, is not influencing the stock.